NCT05102474Completed
Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis
Source: ClinicalTrials.gov · Last updated 6 Aug 2025
Brief summary (registry, in English)
Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 24 (actual)
- First submitted
- 18 Oct 2021
- Start date
- 15 Feb 2022
- Primary completion date
- 3 Jul 2024
- Lead sponsor
- University of California, San Francisco
- Diseases
- Psoriasis
- NCT number
- NCT05102474
What you commit to
- Study type: Observational
- Participants enrolled: 24
- From 15 Feb 2022 to the primary completion date, 3 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having a previous diagnosis of obstructive sleep apnea (OSA) or another medically defined sleep disorder or fall into the intermediate or high-risk groups for having OSA as calculated by the STOP-BANG questionnaire
- Subjects who have used the following treatments for psoriasis: phototherapy (UVB) in the last 2 weeks, photochemotherapy (PUVA) in the last 4 weeks, oral systemic treatments in the last 4 weeks, biologic immunomodulating agents in the last 12 weeks, or have had exposure to any other investigational drug/device within 30 days prior to study entry
Other
- Patients with guttate, erythrodermic, or pustular psoriasis subtypes
- Subjects who have used any over the counter or prescription sleep aids within five half-lives of the agent in question.
Who the study is looking for
- Patients with a diagnosis of moderate to severe plaque type psoriasis confirmed by the principal investigator. Moderate to severe psoriasis will be defined as affected BSA ≥3%. Healthy controls will be age and sex matched (see below) subjects with no prior or current history of psoriasis.
- Are at least 18 years of age
- Psoriasis has been stable over the last 3 months
- Psoriasis is either untreated or treated only with topicals at the current time (see exclusion criteria for washout times)
- Subjectively reported poor sleep quality using the Pittsburg Sleep Quality Index (PSQI) (defined as a global score \>5)
- Fluent in English
- Demonstrate understanding of the study and willingness to participate as evidenced by voluntary informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCSF Psorisis Center Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.